NCT00999752

Brief Summary

The main purpose of this study is to evaluate the effects of Nebivolol and Hydrochlorothiazide on blood pressure in African Americans with high blood pressure.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at below P25 for not_applicable hypertension

Timeline
Completed

Started Oct 2009

Shorter than P25 for not_applicable hypertension

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2009

Completed
20 days until next milestone

First Submitted

Initial submission to the registry

October 21, 2009

Completed
1 day until next milestone

First Posted

Study publicly available on registry

October 22, 2009

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2010

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2010

Completed
Last Updated

May 5, 2011

Status Verified

May 1, 2011

Enrollment Period

4 months

First QC Date

October 21, 2009

Last Update Submit

May 4, 2011

Conditions

Keywords

HypertensionAfrican AmericansArterial StiffnessVascular Resistance

Outcome Measures

Primary Outcomes (1)

  • Changes in systolic and diastolic blood pressure after treatment with nebivolol and reaching normal blood pressure <140/90

    Every visit for 25 weeks (9 study visits)

Secondary Outcomes (1)

  • Differences after nebivolol treatment on diastolic function as measured by tissue doppler imaging (ECHO), arterial compliance and stiffness and vascular nitric oxide availability determined by neutrophil function

    At the begining and end of study

Study Arms (2)

Arm A

ACTIVE COMPARATOR

Nebivolol to reach blood pressure control

Drug: Nebivolol

Arm B

ACTIVE COMPARATOR

Hydrochlorothiazide for blood pressure control

Drug: Hydrochlorothiazide

Interventions

5mg/day with increase to 10 mg/day to reach blood pressure \<140/90

Also known as: Bystolic
Arm A

Hydrochlorothiazide 25 mg/day

Also known as: HCTZ
Arm B

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Known Hypertension by history
  • Self-described African American

You may not qualify if:

  • Uncontrolled Diabetes Mellitus (HbA1C\>10)
  • Known CAD, Cerebrovascular Disease, PVD or Renovascular Disease
  • Liver disease
  • Chronic Renal Disease
  • Uncontrolled Hypertension (\>199 systolic and/or \>115)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Atlanta Vascular Research Foundation

Tucker, Georgia, 30084, United States

Location

MeSH Terms

Conditions

Hypertension

Interventions

NebivololHydrochlorothiazide

Condition Hierarchy (Ancestors)

Vascular DiseasesCardiovascular Diseases

Intervention Hierarchy (Ancestors)

EthanolaminesAmino AlcoholsAlcoholsOrganic ChemicalsAminesBenzopyransPyransHeterocyclic Compounds, 1-RingHeterocyclic CompoundsHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingChlorothiazideBenzothiadiazinesSulfonamidesSulfonesSulfur CompoundsThiazides

Study Officials

  • Bobby V Khan, MD PhD

    InVasc Therapeutics, Inc.

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

October 21, 2009

First Posted

October 22, 2009

Study Start

October 1, 2009

Primary Completion

February 1, 2010

Study Completion

May 1, 2010

Last Updated

May 5, 2011

Record last verified: 2011-05

Locations